Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05232136

OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer Clinical Trial

Official title:
Oncolytic Virus (OH2) Adjuvant Therapy After Transurethral Resection of Bladder Tumor in Non-Muscle-Invasive Bladder Cancer Who Have Failed First-line Prophylactic Intravesical Instillation Therapy: a Phase Ⅰb/Ⅱ Clinical Trial

Clinical Trial Summary

This phase Ⅰb/Ⅱ study evaluates the safety and efficacy of OH2 for adjuvant therapy in non-muscle-invasive bladder cancer after first-line prophylactic intravesical instillation therapy. OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response.

Clinical Trial Description

This is a phase Ⅰb/Ⅱ study evaluating the safety and efficacy of OH2 in non-muscle-invasive bladder cancer. BH-OH2-016 is a single-arm,multicenter clinical trial. After screening, The treatment period includes induction treatment period and maintenance treatment period. In the induction treatment period, OH2 will be delivered once two weeks. In the maintenance treatment period, OH2 will be delivered once a month. In this trial, two doses (1x10e6, 1x10e7 CCID50/mL) of OH2 will be delivered intravesical instillation，and the 1x10e6 CCID50/mL dose group should be delivered before the 1x10e7 CCID50/mL dose group. Adverse events (AEs) are graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0).Urine cytology/Cystoscopy/ultrasonography of urinary system will be used for disease recurrence examination. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05232136
Study type Interventional
Source Binhui Biopharmaceutical Co., Ltd.
Contact JianZhong Shou, MD
Phone 13601332989
Email shoujzh@126.com
Status Recruiting
Phase Phase 1/Phase 2
Start date July 11, 2022
Completion date October 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05483868 - A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer Phase 1
Not yet recruiting NCT05547516 - Blue Laser -5ala Photodynamic Therapy (PDT) in High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients N/A
Not yet recruiting NCT05580354 - Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer Phase 4
Recruiting NCT05519241 - A Phase I Intravesical PPM Therapy for NMIBC Phase 1
Not yet recruiting NCT05002556 - AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer
Recruiting NCT05544552 - Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations Phase 1/Phase 2
Recruiting NCT05796375 - Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance N/A
Active, not recruiting NCT03528694 - Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer Phase 3
Recruiting NCT05790850 - Pre-Habilitation With Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial) N/A
Completed NCT03664258 - A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)
Not yet recruiting NCT05962541 - Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) Phase 4
Active, not recruiting NCT05864599 - External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the CUETO Group
Not yet recruiting NCT03950362 - Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Phase 2
Recruiting NCT05710848 - A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer Phase 1/Phase 2
Recruiting NCT05825950 - Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
Recruiting NCT05626101 - Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study N/A
Recruiting NCT05538663 - Intravesical BCG vs GEMDOCE in NMIBC Phase 3
Recruiting NCT06245759 - The Prognostic Impact of Tumor Location in Non-Muscle-Invasive Bladder Cancer Patients
Active, not recruiting NCT04690699 - LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of Lerapolturev (PVSRIPO) and Lerapolturev in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT05675176 - Antegrade Observational Comparative Study for the Intravesical Instillation Therapy of Bacillus Calmette Guerin With the Use of Different Types of Urinary Catheters in Patients With Urinary Bladder Cancer